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AbstrACt
Objectives A rapid growth in the reported rates of acute 
kidney injury (AKI) has led to calls for greater attention 
and greater resources for improving care. However, the 
reported incidence of AKI also varies more than tenfold 
between previous studies. Some of this variation is likely 
to stem from methodological heterogeneity. This study 
explores the extent of cross-population variation in AKI 
incidence after minimising heterogeneity.
Design Population-based cohort study analysing data 
from electronic health records from three regions in 
the UK through shared analysis code and harmonised 
methodology.
setting Three populations from Scotland, Wales and 
England covering three time periods: Grampian 2003, 
2007 and 2012; Swansea 2007; and Salford 2012.
Participants All residents in each region, aged 15 years 
or older.
Main outcome measures Population incidence of 
AKI and AKI phenotype (severity, recovery, recurrence). 
Determined using shared biochemistry-based AKI episode 
code and standardised by age and sex.
results Respectively, crude AKI rates (per 10 000/year) 
were 131, 138, 139, 151 and 124 (p=0.095), and after 
standardisation for age and sex: 147, 151, 146, 146 
and 142 (p=0.257) for Grampian 2003, 2007 and 2012; 
Swansea 2007; and Salford 2012. The pattern of variation 
in crude rates was robust to any modifications of the AKI 
definition. Across all populations and time periods, AKI rates 
increased substantially with age from ~20 to ~550 per 
10 000/year among those aged <40 and ≥70 years.
Conclusion When harmonised methods are used and 
age and sex differences are accounted for, a similar 
high burden of AKI is consistently observed across 
different populations and time periods (~150 per 10 000/
year). There are particularly high rates of AKI among 
older people. Policy-makers should be careful not draw 
simplistic assumptions about variation in AKI rates based 
on comparisons that are not rigorous in methodological 
terms.
IntrODuCtIOn 
The reported outcomes following acute 
kidney injury (AKI) are consistently poor.1 
Reports of a growth in rates of AKI have led 
to calls for greater attention and resources 
for improving care,2 but there is a more 
than tenfold variation between studies in 
the reported population incidence of AKI.3–7 
Population-based estimates of AKI incidence 
range from 18 per 10 000/year3 to 250 per 
10 000/year5 based on changes in serum 
creatinine over time, and from 3 to 40 per 
10 000/year based on hospital episode codes 
for ‘non-dialysis requiring AKI’.8 9 This wide 
variation is difficult to fully explain,10 but is 
likely to be due in part to a changing clinical 
landscape with evolving international AKI 
criteria,11–14 and different pragmatic interpre-
tations of AKI criteria in research.5 15 These 
reasons for variation are all potential sources 
of bias in clinical studies of AKI (figure 1). 
Without a clearer understanding of why 
populations differ, it is challenging (and 
potentially misleading) to interpret clinical 
strengths and limitations of this study
 ► Previous studies have reported substantial variation 
in the incidence of acute kidney injury (AKI) between 
regions and over time, but have involved heteroge-
neous methods that limit comparability. To our best 
knowledge, this is the first cross-population study 
of AKI incidence within one study, with minimised 
methodological heterogeneity by sharing analysis 
code across regions.
 ► By using consistent methods, and real-life, routinely 
collected healthcare data, we provide new evidence 
that the rates of AKI in the UK are similar across 
different regions and time periods: ~150 events per 
10 000/year (1.5% of the population).
 ► These findings may not be generalisable outside 
of the regions of the UK in the study. However, to 
enable researchers to replicate this work, we have 
made publicly available our analysis code for identi-
fying and characterising AKI episodes.
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research in context, to make comparisons across popu-
lations or over time, or to make informed public health 
recommendations.
Worldwide, health services are undertaking quality 
initiatives to increase clinical awareness and improve 
treatment of AKI16–19 in order to achieve the Inter-
national Society of Nephrology target of eliminating 
avoidable deaths from AKI by 2025.20 To evaluate the 
effectiveness of these initiatives, it is vital that there is a 
harmonisation of approaches to clinical research. This 
Figure 1 Conceptual framework for the reasons for cross-population differences in acute kidney injury (AKI) rates. eGFR, 
estimated glomerular filtration rate; IDMS, isotope dilution mass spectrometry; KDIGO, Kidney Disease: Improving Global 
Outcomes; RRT, renal replacement therapy.
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means minimising methodological heterogeneity so that 
the findings of future research are more comparable, 
and maximising transparency so that trends in disease 
incidence and outcomes can be understood. Method-
ological heterogeneity can arise when researchers extract 
data from different data infrastructures, make different 
assumptions and adopt different criteria for identifying 
events. These steps are particularly important in AKI 
because of the recognised challenges of AKI research: it 
occurs unpredictably, in different clinical locations,21 may 
be transient22 and relies on trends rather than absolute 
values.12–14 Small differences in how these challenges are 
handled can alter both the reported incidence and prog-
nosis of AKI.5 15 21 23 Despite its importance, this informa-
tion is often undocumented or described in insufficient 
detail for research to be reproduced.24 We have described 
these reasons for variation in AKI rates in a conceptual 
model (figure 1).
Algorithms using blood test data from electronic 
health records (EHRs) offer the potential of an objec-
tive common language for observing common diseases 
in clinical practice, audit and research.25 In previous 
work, we developed an extended version of a widely used 
National Health Service (NHS) algorithm for detecting 
AKI in blood tests,26 which flags individual ‘AKI’ blood 
tests and also applies phenotyping methods to combine 
AKI-flagged blood tests into clinically meaningful AKI 
illness episodes grouped by severity, duration, recovery 
and recurrence.27 28 Sharing this algorithm between 
researchers working with different populations provides 
an opportunity to develop a harmonised approach to 
clinical research, robustly comparing the burden of AKI 
across different populations and over time, even when 
patient-level data cannot be shared. We used this to study 
the variation in the incidence of AKI across three popu-
lations from England, Scotland and Wales. The anal-
ysis spans a decade of change in the clinical awareness 
of AKI,16 change in international AKI criteria12–14 and 
change in the emphasis on community surveillance of 
people with chronic diseases.29–31 Our aim was to explore 
the extent of cross-population variation in AKI incidence 
using real-life data, while minimising heterogeneity 
through harmonised methods.
MAterIAls AnD MethODs
Population profiles
This study compares datasets created using linked EHR 
data from primary and secondary care for three UK regions 
with different ‘index’ years from 2003 to 2014: Grampian 
2003, 2007 and 2012; Abertawe Bro Morgannwg Univer-
sity Health Board (ABMU, referred to in this article as 
Swansea) 2007; and Salford 2012 (online supplemen-
tary figure 1). Each dataset involves health data from the 
UK NHS and includes complete primary and secondary 
care biochemistry capture for the region. A fourth 
region initially considered for this analysis (from South 
England) was excluded because initial inspection of the 
data characteristics revealed that the population capture 
of the data source was incomplete and might have led to 
bias in the estimation of AKI. All regions provide public 
healthcare, free at the point of use.
NHS Grampian, a health authority in Scotland, is served 
primarily by one large tertiary hospital and another 
district general hospital. All biochemistry for the dataset 
was extracted from a single biochemistry department 
covering the entire regional population.5 The Grampian 
dataset was linked with the Scottish Renal Registry to 
exclude those already receiving chronic renal replace-
ment therapy (RRT), to avoid misclassification of RRT 
as AKI. Similarly, Salford (North England) represents 
one borough of Greater Manchester, served by a single 
NHS hospital and biochemistry laboratory.32 Read codes 
(version 2) were used to extract biochemistry informa-
tion and exclude records from people receiving chronic 
RRT. In contrast, ABMU (Swansea, Wales) in 2007 
covered a region served by four district general hospitals 
and four laboratories using two information management 
systems.33 34 Those receiving chronic RRT could not be 
directly determined from a register but could be excluded 
based on the hospital location marked on the blood tests.
To provide further contextual description of these 
populations, we collected information on population 
mortality and relevant morbidities (renal and vascular) 
from the Office of National Statistics, UK Renal Registry, 
and Quality Outcomes Framework (QOF) data entered 
by general practitioner (GP) practices (table 1). Impor-
tantly, QOF data represent incentivised recording by GPs 
of people with a given condition (eg, chronic kidney 
disease), rather than actual population prevalences. 
This means that small differences in prevalence on the 
disease registers may represent recording practice as well 
as actual disease prevalence and should be interpreted 
with caution.
Conceptual framework
In figure 1, we provide a conceptual framework for under-
standing the sources of variation in AKI revealed by our 
analysis. We sought to minimise ‘artefactual’ methodolog-
ical differences in AKI episode rates by using only data-
sets where complete data capture (from both hospital 
and community settings) was possible, by harmonising 
data preparation and cleaning, and by standardising 
code sets for identifying AKI episodes. We also accounted 
for ‘real’ potential sources of variation in AKI rates by 
performing age and sex standardisation, stratification by 
baseline eGFR for case-mix differences and comparing 
the number of people with blood tests in rapid succession 
as a surrogate for presence of an acute illness.
Data extraction and processing
This study used a distributed analysis approach to 
protect the confidentiality of patient-level data. Data 
were analysed by on-site researchers working from 
the same code. Non-disclosive summary statistics were 
aggregated into a single dataset, which was analysed 
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centrally. This ensured that patient-level data were 
never brought together in a single physical location. 
All serum creatinine results for each individual were 
extracted. Creatinine values that were missing, were 
a non-value (eg, ‘sample inadequate’, ‘sample error’) 
or were lower than the limit for detection of the anal-
yser were excluded. The ‘Modification of Diet in Renal 
Disease’ study estimated glomerular filtration rate 
(eGFR) was calculated using the abbreviated four-vari-
able equation.35 Finally, to avoid a non-chronological 
evaluation of samples from different locations, where 
multiple samples were available for the same individual 
on a given day, the sample with the highest creatinine 
value was retained for analysis.
Table 1 Contextual information on the populations in this study
Grampian
2003
Grampian
2007
Grampian
2012
Swansea
2007
Salford
2012
Midyear regional population (all ages) 
during index year*
529 360 548 290 573 400 499 400 237 085
Midyear regional adult population 
(age ≥15 years) during index year*
438 332 458 900 482 444 415 500 193 882
Percentage of population in urban 
settlements of >10 000
people†
49.3% 51.8% 52.1% 81.7% 99.9%
Regional crude all-cause mortality rate 
ages 15+ (index year/100 000)*
1192 1154 1093 1334 1135
Crude adult incidence of chronic RRT per 
million population (UKRR)‡
98 102 93 167 85
Prevalence of chronic kidney disease per 
100 people (QOF)§
NA¶ 2.6 3.3 1.8 3.0
Prevalence of coronary heart
disease per 100 people (QOF)§
4.1 4.0 3.9 4.1 3.9
Prevalence of diabetes registration per 
100 people (QOF)§
3.0 3.3 4.2 4.3 4.5
Prevalence of heart
failure registration per 100 people (QOF)§
NA§ 0.8 0.8 1.0 0.9
Prevalence of hypertension registration 
per 100 people (QOF)§
11.0 11.7 13.2 12.5 13.8
Prevalence of stroke and 
TIA registration per 100 people (QOF)§
1.6 1.7 1.9 2.1 1.8
No of biochemistry departments for whole 
region
One 
department 
covers in and 
outpatient, 
community 
and private 
tests
One 
department 
covers in and 
outpatient, 
community 
and private 
tests
One 
department 
covers in and 
outpatient, 
community 
and private 
tests
Four departments 
cover in and 
outpatients, 
community and 
private tests
One department 
covers in and 
outpatient and 
community 
tests. Privately 
obtained samples 
unavailable
Means of excluding samples belonging to 
people on long term RRT from dataset
Link to 
Scottish 
Renal 
Registry
Link to 
Scottish 
Renal 
Registry
Link to 
Scottish 
Renal 
Registry
Removing 
samples from 
locations where 
renal replacement 
is performed, 
including intensive 
care unit
Read code 
screening
IDMS aligned creatinine assay Yes Yes Yes From 2007 Yes 
*From the Office of National Statistics.
†From the 2011 national census in England and Wales and Scottish government urban rural classification.
‡From the UK renal registry (UKRR) annual reports.
§Quality outcomes framework (QOF) data are incentivised information entered by general practitioner practices. Not recorded in Grampian in 
2003, for which 2004 data are provided where available.
¶Data not available.
IDMS, isotope dilution mass spectrometry; NA, not applicable; RRT, renal replacement therapy; TIA, Transient ischaemic attack; UKRR, UK 
Renal Registry.
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AKI identification and phenotyping
A challenge of AKI clinical research is the operational-
isation of precise international AKI criteria in ‘real-life’ 
data where people do not receive blood tests in a proto-
colised fashion. Blood tests may not have been done at 
the necessary times to directly observe an acute rise in 
creatinine from a previous baseline, and assumptions 
based on available data are required. We identified 
differences in assumptions for determining AKI as an 
important potential methodological reason for observed 
variation in AKI rates (figure 1) and therefore used the 
exact same definition and analysis code in each region. 
Kidney Disease: Improving Global Outcomes (KDIGO)-
based AKI detection and phenotyping algorithm code 
was applied by separate analysts working locally on each 
dataset.14 As summarised in online supplementary table 
1, these criteria compare each blood test with previous 
‘baseline’ results within the last 365 days (‘the look-back 
period’) to determine if a recent change has occurred.27 
Where AKI occurred, a ‘look-forward period’ of 90 days 
was used to follow and phenotype the whole AKI episode. 
In online supplementary figure 2, these look-back and 
look-forward time periods are illustrated for a single hypo-
thetical patient with respect to a moment of developing 
AKI within the index year. For those without AKI, the first 
eGFR of the index year was used as the baseline eGFR. 
For convenience, we used a baseline eGFR <60 mL/
min/1.72 m2 as an indicator of chronic kidney disease. 
Shared Stata code provided the following outputs: 
number of blood tests consistent with AKI, number of 
AKI episodes, baseline eGFR, AKI episode severity stage, 
progression of AKI severity from a lower to higher stage, 
recovery to baseline within 90 days and presence of prior 
AKI episodes in the past 3 years (ie, making the episode a 
recurrent AKI episode).
We also analysed data using more parsimonious 
versions of the KDIGO criteria: a ‘narrow interpretation’ 
in which blood tests were only compared if they were no 
more than a week apart (ie, restricted to criteria 2 and 3), 
and a ‘very narrow interpretation’ comparing only tests 
no more than 2 days apart (ie, restricted to criterion 3). 
If variation was due to a lack of robustness of AKI criteria 
in the face of estimating baseline from less recent data, 
these narrower interpretations would be expected to lead 
to less variation in AKI incidence.
To ensure uniformity of the application and interpre-
tation of AKI code, a mock dataset of 40 hypothetical 
patients was developed. This mock dataset deliberately 
contained unformatted variables and a variety of creat-
inine trend patterns to represent a full range of data 
cleaning steps, AKI phenotypes, blood test intervals and 
interpretation issues. Each analyst used the same code on 
the test dataset and reproduced the same results before 
progressing to analysing regional data. We have made 
the algorithm code, mock dataset and instructions for 
their optimal use in Stata freely available online (https:// 
github. com/ RenalHDRUK).
statistical analysis
Analyses included the description of baseline characteris-
tics, comparison of both crude and age-sex standardised 
rates of AKI, and phenotypes of AKI episodes. We also 
compared AKI rates in subgroups of baseline eGFR (as 
described above) and individual components of AKI 
criteria to determine if variations in rate were robust to 
changes in the AKI definition (table 2). AKI can only 
be identified when sufficient blood tests have been 
performed to detect a change. Therefore, to evaluate 
reasons for residual variation, we described the patterns 
of blood testing in each region, including the frequency 
of blood tests, the regularity (eg, blood tests no more 
than 2 and 7 days apart) and blood test location (hospital 
and outpatient/community).
Baseline characteristics included age, sex, the 
number of people with evidence of renal impairment 
(eGFR <60 mL/min/1.73 m2) on their first test in the 
index year and the number of people with blood tests 
sufficiently close together for it to be possible to detect 
an ‘AKI’ result if present (two tests no more than 365 days 
apart).
We compared population rates of AKI episodes across 
each region and index year. We compared AKI episode 
rates using national statistics midyear population esti-
mates for each region and then standardised to the 
England population for 2012,36 a reference population 
selected as two of the three regions provided 2012 data. 
All AKI episodes in the index year counted towards the 
overall AKI episode rate. One-way analysis of variance 
followed by Tukey’s post hoc test (in the event of signifi-
cant differences) was used to identify pairwise significant 
differences in population level AKI episode rates.
For people with sufficient blood tests to potentially 
detect an episode of AKI (at least two tests no more 
than 365 days apart), we compared rates within eGFR 
strata (<30, 30–44, 45–59 and ≥60 mL/min/1.73 m2). 
The proportion of the population with at least one AKI 
result based on AKI criteria 1, 2 or 3 (table 2), and the 
proportion of the population with at least one AKI result 
based on narrower interpretations of KDIGO criteria 
(restricting to criteria 2 and 3, or criterion 3 alone) were 
also recorded. To evaluate the impact of incomplete 
biochemistry capture, we also recalculated AKI rates 
using only tests taken from people in hospital. Of note, 
a distinction between hospital inpatient and outpatient 
results was not possible in Salford.
To evaluate potential sources of residual variation 
in AKI rates after harmonised analysis, we compared 
patterns of blood testing (number, frequency and 
location).
Patient involvement
No patients were involved in development of the research 
question or the design of the study. There are no plans 
to disseminate the results of the research to study 
participants.
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results
Populations and baseline characteristics
As described in table 1, populations ranged in size from 
193 882 (Salford 2012) to 482 444 people (Grampian 
2012) (table 3). Crude reported population mortality 
rates were higher in Swansea than Grampian and Salford, 
as was the incidence of people starting long-term RRT. 
The recognition of diabetes and cardiovascular diseases 
in incentivised GP registers was similar across the 
populations.
Table 2 shows the baseline characteristics of extracted 
datasets after harmonised data cleaning. The percentage 
of people with at least two tests no more than 365 days 
apart varied from 17% to 25% with the fewest in the 
earliest dataset (Grampian 2003). There was a greater 
proportion of people tested with renal impairment 
(eGFR <60 mL/min/1.73 m2) in 2007 compared with the 
other years of study.
Incidence of AKI episodes
Table 3 and figure 2 show the differences in crude and 
standardised rates of AKI episodes for each dataset. A 
minority of people had more than one AKI episode in 
the index year. For reporting AKI episode rates (table 3), 
all episodes are included, whereas for reporting pheno-
types of people with an AKI episode, the first episode is 
described (bottom of table 3 and table 4). Crude AKI 
rates varied with the lowest in Salford 2012 and highest 
rate in Swansea 2007 (124–151 per 10 000/year, p=0.095). 
Standardisation by age and sex accounted for residual 
differences (142–151 per 10 000/year, p=0.257), with 
95% CIs overlapping in all instances. Age and sex stan-
dardised AKI rates varied little between Grampian 2003, 
2007 and 2012 (146–151 per 10 000/year). Table 3 also 
shows that the majority of people developing AKI could 
be identified using hospital tests alone, and just over half 
could be identified in each region using a rigid interpre-
tation of KDIGO AKI criteria. Finally, across all popula-
tions, the proportion of people developing AKI in the 
index year increased substantially with increasing age and 
lower eGFR.
As shown in figure 3, the pattern of variation in crude 
AKI rates was the same when narrower interpretations of 
KDIGO AKI criteria were used, comparing only blood 
tests in the prior 2 and 7 days. Table 4 shows this pattern 
was also similar when analysis was limited to each indi-
vidual component of the AKI criteria, or within strata of 
baseline eGFR.
AKI phenotypes
Table 4 describes the first AKI episode for people with an 
AKI episode during the index year. As well as having the 
highest crude AKI rate, a greater proportion of those with 
AKI in Swansea were older, had baseline eGFR <60 mL/
min/1.73 m2 (37.6%), had a severe AKI episode (15.4% 
stage 3) and had non-recovery at 90 days (45.1%). In 
Table 2 Baseline characteristics for each dataset
Grampian 2003 Grampian 2007 Grampian 2012 Swansea 2007 Salford 2012
Patient total (%) Patient total (%) Patient total (%) Patient total (%) Patient total (%)
Adult resident population 
(aged ≥15)
438 332 458 900 482 444 415 500 193 882
 
Population ascertainment of renal impairment (eGFR <60 mL/min/1.73 m2) in index year
  No tests during index year 311 922 (71.2)* 303 673 (66.2) 301 992 (62.6) 253 531 (61.0) 116 977 (60.3)
  eGFR ≥60† 101 595 (23.2) 120 854 (26.3) 158 736 (32.9) 129 959 (31.3) 66 890 (34.5)
  eGFR <60† 24 805 (5.7) 34 373 (11.3) 21 716 (4.5) 32 010 (7.7) 10 015 (5.2)
 
Sufficiency of tests to enable AKI detection
  People with no tests during 
index year
311 922 (71.2) 303 673 (66.2) 301 992 (62.6) 253 531 (61.0) 116 977 (60.3)
  People with insufficient tests 52 602 (12.0) 57 788 (12.6) 69 239 (14.4) 59 839 (14.4) 31 467 (16.2)
  People with ≥2 tests within 
365 days
73 808 (16.8) 97 439 (21.2) 111 213 (23.1) 102 130 (24.6) 45 438 (23.4)
 
Characteristics of people with ≥2 tests within 365 days
  Proportion women 40 413 (54.8) 53 061 (54.5) 60 330 (54.2) 55 685 (54.5) 24 723 (54.4)
  Median age (IQR) 63 (48–74) 63 (50–75) 63 (49–74) 64 (51–75) 63 (49–74)
  eGFR <60† 18 573 (25.2)‡ 28 274 (29.0) 18 679 (20.2) 25 952 (25.4) 8541 (18.8)
*Expressed as a percentage of total residents unless specified otherwise.
†First eGFR in index year (mL/min/1.73 m2).
‡Expressed as a percentage of people with ≥2 tests within 365 days.
AKI, acute kidney injury; eGFR, estimated glomerular filtration rate.
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Grampian between 2003 and 2012, there was a steady 
improvement in the proportion of people with renal 
recovery 90 days after AKI from 42% to 49%.
Further sources of variation
In addition to assessing for age, sex and case-mix differ-
ences, we evaluated the blood testing patterns and 
Figure 2 Crude and age–sex standardised rate of acute kidney injury (AKI) episodes.
Table 4 Phenotype of acute kidney injury (AKI) episodes 
Grampian 2003 Grampian 2007 Grampian 2012 Swansea 2007 Salford 2012
Total people (%) Total people (%) Total people (%) Total people (%) Total people (%)
People with AKI* 5362 5930 6277 5847 2208
  Proportion women 2899 (54.1) 3256 (54.9) 3443 (54.9) 3195 (54.6) 1250 (56.6)
  Median age (IQR) 73 (61–81) 74 (61–82) 74 (60–82) 76 (64–84) 74 (61–83)
 
Peak AKI severity stage for first episode
  Stage 1 3720 (69.4) 4211 (71.0) 4389 (69.9) 3720 (63.6) 1435 (65.0)
  Stage 2 1014 (18.9) 1063 (17.9) 1174 (18.7) 1224 (20.9) 451 (20.4)
  Stage 3 628 (11.7) 656 (11.1) 714 (11.4) 903 (15.4) 322 (14.6)
  AKI stage progression 817 (15.2) 792 (13.4) 850 (13.5) 900 (15.4) 300 (13.6)
 
Baseline eGFR for first episode (mL/min/1.73 m2)
  ≥60 3612 (67.4) 3874 (65.3) 4419 (70.4) 3648 (62.4) 1512 (68.5)
  45–59 809 (15.1) 940 (15.9) 894 (14.2) 1044 (17.9) 323 (14.6)
  30–44 597 (11.1) 723 (12.2) 661 (10.5) 732 (12.5) 202 (9.1)
  <30 344 (6.4) 393 (6.6) 303 (4.8) 423 (7.2) 171 (7.7)
 
Prior AKI episodes detected in last 3 years
  No prior episodes 4415 (82.3) 4847 (81.7) 5052 (80.5) 4824 (82.5) 1708 (77.4)
  One prior episode 723 (13.5) 833 (14.0) 897 (14.3) 784 (13.4) 349 (15.8)
  Two or more prior 
episodes
224 (4.2) 250 (4.2) 328 (5.2) 239 (4.1) 151 (6.8)
  Prior AKI within 1 year 414 (7.7) 459 (7.7) 492 (7.8) 488 (8.3) 216 (9.8)
 
Renal recovery to within 20% of baseline
  Renal recovery 2239 (41.8) 2588 (43.6) 3077 (49.0) 2156 (36.9) 970 (43.9)
  Renal non-recovery 2203 (41.1) 2387 (40.3) 2245 (35.8) 2635 (45.1) 820 (37.1)
  Repeat samples not 
available
920 (17.2) 955 (16.1) 955 (15.2) 1056 (18.1) 418 (18.9)
*Numbers in brackets expressed as a percentage of people with at least one AKI episode.
eGFR, estimated glomerular filtration rate.
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clinical location contexts of each dataset (figure 4). 
Figure 4A shows the frequency of blood tests taken 
grouped by location: hospital inpatient or outpatient/
community. Figure 4B shows the proportion of people 
with blood tests in close succession. In Grampian from 
2003 to 2012, community blood testing increased over 
time, but the frequency of hospital inpatient testing 
remained unchanged. Test location was not available in 
Salford, but the proportions of people with two blood 
tests no more than 2 and 7 days apart was lower than in 
Grampian and Swansea. Figure 1 shows the conceptual 
framework for understanding these sources of variation.
Figure 3 Crude acute kidney injury (AKI) rates using different interpretations of the Kidney Disease: Improving Global 
Outcomes-based AKI definition.
Figure 4 Patterns of blood testing by clinical location (A) and by test regularity (B).
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DIsCussIOn
To our knowledge, this is the first multicentre study to 
systematically evaluate the extent of and reasons for 
regional and temporal variation in population rates of 
AKI, using a harmonised methodological approach. 
There were differences in the crude rates of AKI between 
datasets, but after accounting for age and sex, stan-
dardised rates were strikingly similar (at 140–150 episodes 
per 10 000/year, or ~1.5% of the population). The consis-
tently high proportion of people aged over 70 developing 
AKI was also striking (>5%) and has implications for the 
planning the future healthcare requirements of an ageing 
population. This analysis shows the importance of both 
harmonised methods and standardisation for case-mix 
prior to any between-centre comparisons for description 
of variation in AKI.
Our analysis provides additional insight into previous 
reports of a rising AKI incidence in studies based on 
hospital episode codes or differing AKI definitions.10 
Applying the same KDIGO-based AKI definition to 
data from the same region, over a 10-year span (2003–
2012), the standardised AKI rates in Grampian changed 
little. Notably, this stability was in spite of an increasing 
frequency of outpatient/community testing in Gram-
pian (whereas the frequency of hospital inpatient testing 
changed little over the same period). In addition, our 
analysis showed similar (although reduced) AKI rates 
across the regions when only hospital blood samples were 
analysed, or when the AKI definition was limited on only 
blood tests within the past week. Our analysis also showed 
a pattern of AKI phenotypes that was consistent with 
case-mix differences between regions. Swansea, which 
had the highest all-cause population mortality, also had 
the highest proportion of AKI phenotypes for severity, 
AKI progression and non-recovery.
Between-population variation in the prevalence of 
kidney disease has previously been described for CKD 
in Ireland,37 Germany38 and Taiwan,39 as have variation 
between European countries.40 In our analysis, we have 
now shown that much of the regional variation in AKI 
between UK regions can be eliminated by harmonising 
methods, definitions and correcting for age and sex 
differences. The stability we report in the AKI incidence 
over multiple time points in a 10-year period is contrary 
to previous studies from the UK and North America.10 
Given the precautions that we took to minimise hetero-
geneity, it is possible that some differences reported in 
previous studies represent a methodological artefact 
(eg, data capture or case-mix). Consistent with our find-
ings, a recent study of hospital-based AKI among people 
admitted to the Mayo Clinic also found no significant 
change in AKI rates between 2006 and 2014 using a 
consistent creatinine change AKI definition across each 
year and stratifying by age and sex.41 Furthermore, in our 
analysis, the pattern of differences in crude AKI rates was 
robust to modifications of KDIGO criteria using shorter 
look-back periods.
Our study has caveats common to observational studies, 
which we have highlighted in a conceptual model that 
explains the reasons for observed variation in AKI rates 
(figure 1). In particular, even though we used data from 
three regions with the same social healthcare system (the 
UK National Health Service), we encountered incomplete 
population data capture that led to the exclusion of a 
fourth region from the study. As we note in figure 1, differ-
ences in population capture arising out of incomplete 
data extraction are not necessarily visible to researchers 
analysing anonymised large datasets. This serves as a 
critical caution for researchers and policy-makers to 
avoid making simplistic assumptions that data from 
different regions are necessarily comparable when they 
are derived from different sources. We note that while we 
have used data from GP registers to provide contextual 
information on the populations, these data need to be 
interpreted carefully as they also reflect recording prac-
tices in primary care rather than solely disease burden. 
We would also like to remind readers that while we have 
applied AKI criteria consistently with the same code in 
each region, where sparse data exist, there still may have 
been bidirectional misclassification between AKI and 
CKD. Similarly, where AKI has occurred in the context 
of critical illness, falsely low creatinine values from loss 
of muscle mass may imply a renal recovery that has not 
occurred. This is a challenge for all observational studies 
using routine blood test data. Nevertheless, a strength 
of our analysis is that we have used the same pragmatic 
approach to this challenge across each of the populations 
and time periods in the study. Finally, we note that only 
data from three UK regions were available for inclusion 
in our study. This is insufficient to describe variation for 
the whole of the UK and other countries. This article 
represents a first step towards more harmonised compari-
sons of AKI across populations. We have shared our code 
with this article (https:// github. com/ RenalHDRUK) 
and now invite researchers working with population data-
sets in other regions to add to our experience.
In conclusion, our analysis shows the need for a robust 
methodological approach and recognition of case-mix 
differences when evaluating between-centre and temporal 
trends in AKI. The sharing of code is key to this approach, 
and we have made our code from this article available for 
researchers to use. Using this approach, we show strik-
ingly similar rates of AKI across different populations 
from England, Scotland and Wales over a 10-year period. 
A consistently high burden of AKI is apparent with an 
estimated 1.5% of the UK population experiencing AKI 
each year, rising to more than 5% per year in the elderly. 
Current quality initiatives should adopt these methods or 
similar methods when evaluating the impact of changes 
in practice on the burden of AKI.
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